Coral Laboratories Limited

Equities

CORALAB6

INE683E01017

Pharmaceuticals

Delayed Bombay S.E. 06:00:56 2024-07-16 EDT 5-day change 1st Jan Change
710.4 INR -1.88% Intraday chart for Coral Laboratories Limited +2.44% +63.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Coral Laboratories Limited Announces Resignation of Ruchi Pipara as Company Secretary and Compliance Officer, with Effect from July 13, 2024 CI
Coral Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Coral Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Coral Laboratories Limited Appoints Ruchi Pipara as Company Secretary, Compliance Officer and Key Managerial Personnel CI
Coral Laboratories Limited Announces Change in Registered Office Address CI
Coral Laboratories Limited Announces Resignation of Shifa Memon as Company Secretary, Compliance Officer and Key Managerial Personnel CI
Coral Laboratories Limited Appoints Shifa Memon as Company Secretary and Compliance Officer, with Effect from March 9, 2024 CI
Coral Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Coral Laboratories Limited Announces Change in Registered Office Address CI
Coral Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Coral Laboratories Limited Approves the Shifting of Registered Office CI
Coral Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Coral Laboratories Limited Approves Alteration of Memorandum of Association CI
Coral Laboratories Limited Proposes Alteration of Memorandum of Association of the Company CI
Coral Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Coral Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Coral Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Coral Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Coral Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Coral Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Coral Laboratories Limited Receives Resignation of Sanket Mehta as Independent Director CI
Coral Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Coral Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Coral Laboratories Limited Announces the Resignation of Purvi Doshi as Non -Executive Director of the Company CI
Coral Laboratories Limited Appoints Rajendrasinh Rana as an Additional Director CI
Chart Coral Laboratories Limited
More charts
Coral Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in the business of pharmaceutical formulations. The Company is engaged in the manufacturing of generic - branded, nutraceuticals, over the counter (OTC) and herbal medicines. It offers dosage forms, which include tablets, capsules, liquid orals, injections (liquids and powder), ointment and creams, gels and lotions, and suppositories. Its product categories include nutraceutical, OTC, sterile and non-sterile. Its nutraceutical products include DAX 200, DAX 400 Drops, Zest drops and Super Zestcal Tablets. Its OTC products include herbal range, skin care, medical devices and effervescent range. Its sterile products include small volume liquid - injectables, lyophilized range - injectables, eye drops and ear drops. Its non-sterile antibiotics/antibacterials, antifungals, gastro-intestinal drugs, anti-emetics and muscle relaxants. The Company also exports its products to various countries.
More about the company
  1. Stock Market
  2. Equities
  3. CORALAB6 Stock
  4. News Coral Laboratories Limited
  5. Coral Laboratories Board to Consider Final Dividend for Fiscal 2024